Abdomen

Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma

Retrieved on: 
Wednesday, November 29, 2023
NY-ESO-1, Lung cancer, Neoplasm, Antigen, Tumor microenvironment, Immune system, Research, Sarcoma, American Cancer Society, Melanoma, Cancer, Swelling, Abdomen, Paul Ehrlich Institute, MAGE-A3, Patient, Pembrolizumab, Medical imaging

PeptiCRAd-1 is made up of ValoTx’s proprietary oncolytic virus, VALO-D102, coated with MAGE-A3 and NY-ESO-1 peptides.

Key Points: 
  • PeptiCRAd-1 is made up of ValoTx’s proprietary oncolytic virus, VALO-D102, coated with MAGE-A3 and NY-ESO-1 peptides.
  • ValoTx’s Phase I, first-in-human trial of PeptiCRAd-1 is currently in three tumor types: melanoma, triple negative breast cancer and non-small cell lung cancer.
  • These sub-types of sarcoma are particularly interesting as they have very high expression levels of our two target antigens.
  • If you are a cancer patient interested in participating in the study, please see the “For Patients” section on valotx.com for more information.

Dr Ivan Puah Developed MDC-Sculpt®️ Lipo Technique To Achieve Optimal Liposuction Results In Patients

Retrieved on: 
Tuesday, November 28, 2023
Lipo, Face, Abdomen, Patient, Elasticity, MDC, Science, Adipose tissue, Skin

Clinic, who has been performing liposuction, correction surgery and gynecomastia surgery for more than 15 years, has developed a liposuction technique called MDC-Sculpt®️Lipo technique .

Key Points: 
  • Clinic, who has been performing liposuction, correction surgery and gynecomastia surgery for more than 15 years, has developed a liposuction technique called MDC-Sculpt®️Lipo technique .
  • This proprietary approach is to achieve the three main objectives of successful and optimal contouring results for patients – thorough fat removal, precise body sculpting and skin tightening.
  • According to Dr Ivan Puah, "Body fat characteristics, thickness and distribution, are just like fingerprints and are unique for each individual.
  • With the MDC-Sculpt®️ Lipo technique, doctors can produce predictable and desirable results for these patients.

Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites

Retrieved on: 
Wednesday, December 20, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Peritoneal cavity, Ascites, Food, Cirrhosis, Orphan, Cancer, Abdomen, Patient, Diagnosis, Therapy, ESLD, Hepatorenal syndrome, Pharmaceutical industry

“The FDA granting Orphan Drug Designation for OCE-205 in ascites is validation of the tremendous need for improved therapies offering novel approaches for patients and supports our clinical focus on this important indication,” said Lise Kjems, M.D., Ph.D., chief medical officer at Ocelot Bio.

Key Points: 
  • “The FDA granting Orphan Drug Designation for OCE-205 in ascites is validation of the tremendous need for improved therapies offering novel approaches for patients and supports our clinical focus on this important indication,” said Lise Kjems, M.D., Ph.D., chief medical officer at Ocelot Bio.
  • The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States.
  • Orphan Drug Designation provides Ocelot Bio certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for its designated indication.
  • This is the second Orphan Drug Designation for OCE-205, which previously received the designation in hepatorenal syndrome.

Opening on March 16: Largest retrospective of Marina Abramović ever held in the Netherlands opens at Stedelijk Museum Amsterdam

Retrieved on: 
Thursday, December 21, 2023
Consciousness, Artist, Rest Energy, Hockey, Culture, Partnership, Royal, Movement, Stedelijk Museum Amsterdam, Spirituality, Hand, The Artist Is Present, Pain, Female, The Hero, Rhythm 0, Fasting, Disability, Amsterdam Museum, Meditation, Abdomen, Emotion, Death, Better, ABN AMRO, Exhibition, Autobiography, Poverty, Sport, ABN, Venice Biennale, Endurance, Royal Academy of Arts, Dragon, Nature, Spiritual body, House, Entertainment

After staging the major retrospective of Ulay's work in 2020, we now proudly open the doors of the museum to Marina Abramović, who has a long and meaningful relationship with the Stedelijk.

Key Points: 
  • After staging the major retrospective of Ulay's work in 2020, we now proudly open the doors of the museum to Marina Abramović, who has a long and meaningful relationship with the Stedelijk.
  • The exhibition Marina Abramović is organized by the Stedelijk Museum Amsterdam and the Royal Academy of Arts, London.
  • The version of the retrospective presented in the Netherlands was organized by curators Karen Archey and Nina Folkersma.
  • The exhibition is generously supported by Art Mentor Foundation Lucerne, the Blockbusterfonds, the benefactors of the Marina Abramović Circle, and the benefactors of the Stedelijk Museum Fonds.

Opening on March 16: Largest retrospective of Marina Abramović ever held in the Netherlands opens at Stedelijk Museum Amsterdam

Retrieved on: 
Thursday, December 21, 2023
Consciousness, Artist, Rest Energy, Hockey, Culture, Partnership, Royal, Movement, Stedelijk Museum Amsterdam, Spirituality, Hand, The Artist Is Present, Pain, Female, The Hero, Rhythm 0, Fasting, Disability, Amsterdam Museum, Meditation, Abdomen, Emotion, Death, Better, ABN AMRO, Exhibition, Autobiography, Poverty, Sport, ABN, Venice Biennale, Endurance, Royal Academy of Arts, Dragon, Nature, Spiritual body, House, Entertainment

After staging the major retrospective of Ulay's work in 2020, we now proudly open the doors of the museum to Marina Abramović, who has a long and meaningful relationship with the Stedelijk.

Key Points: 
  • After staging the major retrospective of Ulay's work in 2020, we now proudly open the doors of the museum to Marina Abramović, who has a long and meaningful relationship with the Stedelijk.
  • The exhibition Marina Abramović is organized by the Stedelijk Museum Amsterdam and the Royal Academy of Arts, London.
  • The version of the retrospective presented in the Netherlands was organized by curators Karen Archey and Nina Folkersma.
  • The exhibition is generously supported by Art Mentor Foundation Lucerne, the Blockbusterfonds, the benefactors of the Marina Abramović Circle, and the benefactors of the Stedelijk Museum Fonds.

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Hepatology, Cirrhosis, Safety, Randomness, Insulin resistance, Food, TIPS, Incidence, AASLD, Liver, Ascites, Abdomen, Hyponatremia, Patient, Confirmatory trial, Liver transplantation, Control, Survival rate, Inflammation, Liver support system, Terlipressin, Dementia, Standard of care, Acceleration, Orphan, SOC, Poster, Pharmaceutical industry, Medical imaging, Boston

CARSON CITY, Nev., Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced positive clinical safety data from the Company’s Phase 2b open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, with standard of care (SOC) in patients with refractory ascites due to cirrhosis. The data will be highlighted today in a late-breaking poster presentation titled “Safety and Tolerability of Continuous Infusion Terlipressin (BIV201) In Patients with Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study” at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023 in Boston, MA.

Key Points: 
  • The incidence of treatment emergent adverse events (TEAEs), including serious TEAEs, was similar in both treatment groups.
  • Two patients who received BIV201 experienced hyponatremia that developed gradually, was asymptomatic, and was resolved upon discontinuation of the study drug.
  • Primary endpoints were safety and tolerability, and incidence of certain complications (Grade ≥2) during the 180 days following randomization.
  • BIV201, a continuous infusion of terlipressin, received Orphan Drug Designation for treatment of ascites from the U.S. Food and Drug Administration in 2017.

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

Retrieved on: 
Thursday, December 14, 2023
Children, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Family, Consumer, Science, Parenting, Neuroblastoma, Tenderness, Urine, Pneumonia, Huber loss, Somatic symptom disorder, Patient, Otitis media, Diagnosis, Tiffany Aching, Bruise, Liver, Chills, Hospital, Hearing loss, Vomiting, Food, Chair, American Cancer Society, EFS, Nose, Mortality, Multimedia, Division, Hematology, Pennsylvania State University, Blood, Diarrhea, Kool-Aid, Bleeding, Nausea, Development, Skin infection, Shivering, Urinary tract infection, Cough, Consortium, Risk, Sinusitis, Humble, Texas, Pain, Skin, Eflornithine, Hope, Upper respiratory tract infection, Disease, Abdomen, Tablet, Pediatric Hematology and Oncology, Sneeze, MD, Death, Immunotherapy, Pharmaceutical industry, Medical device, Nursing, Birth control, Phosphorus, Fever, USWM

High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.

Key Points: 
  • High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.
  • US WorldMeds partnered with the Beat Childhood Cancer Research Consortium at Penn State University, which conducted the preclinical and clinical research to help advance this vital therapy.
  • The Consortium represents a group of over 50 hospitals that offer collaboration through a network of childhood cancer clinical trials.
  • “We are thankful for the dedication of our partners, specifically the Beat Childhood Cancer Research Consortium, who work tirelessly to improve treatment outcomes for pediatric cancer patients.

Non-surgical Cosmetic Procedures Market report from 2022-2027 by Technavio - The market size to grow by USD 11.99 billion during the forecast period

Retrieved on: 
Friday, December 15, 2023
PRP, Woman, Neck, Safety, Peel (fruit), Engineering, Face, Scar, Chin, ROW, Smash Mouth, Lifting, Regeneration, Abdomen, Tissue, Injectable filler, Platelet-rich plasma, AB toxin, Rejuvenation, USD, Buttocks, Pigment, Bacteria, Chemical substance, Filler (linguistics), Blood, Compound annual growth rate, Ageing, Growth, Common, Skin, Physiology, Overalls, Injection, Injection (medicine), Hair removal, Medical device, Dentistry, Cosmetics, Beauty salon, Medical imaging, Botulinum toxin, Fat removal procedures

Within the domain of aesthetic enhancements, plastic surgeons spearhead the evolution of minimally invasive procedures, leveraging remarkable technological advancements.

Key Points: 
  • Within the domain of aesthetic enhancements, plastic surgeons spearhead the evolution of minimally invasive procedures, leveraging remarkable technological advancements.
  • Laser Hair Removal: Laser hair removal is a popular cosmetic procedure that utilizes concentrated beams of light to remove unwanted hair.
  • Non-surgical Skin Tightening Market: The non-surgical skin tightening market size is estimated to grow at a CAGR of 7.61% between 2023 and 2027.
  • Aesthetic Lasers Market: The global aesthetic lasers market size is estimated to grow by USD 1,264.98 million at a CAGR of 11.94% between 2023 and 2028.

Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches

Retrieved on: 
Sunday, December 10, 2023
Human, Woman, ASH, Patient, Research, Infection, Navitoclax, Venetoclax, Cancer, Doctor of Philosophy, Anemia, Mutation, Bone marrow, Food, Progression-free survival, Acute myeloid leukemia, Leukemia, Male, AbbVie, Blood, Diarrhea, Bleeding, Family, Ruxolitinib, Society, San Diego Convention Center, Primary myelofibrosis, Spleen, SAN, Data, PFS, MD Anderson Cancer Center, University, Splenomegaly, Phase, Pain, Cell, B cell, JAK, FCR, Disease, Abdomen, Fatigue, MRD, Weakness, Chronic lymphocytic leukemia, Standard of care, MB, CLL, Lymphoma, Pharmaceutical industry, Medical imaging, Dentistry, Vaccine, Medical device, MD

SAN DIEGO, Dec. 10, 2023 /PRNewswire/ -- Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, and how a powerful, relatively new prognostic tool is helping identify patients who are more or less likely to benefit from both older and newer treatments.

Key Points: 
  • Two other studies presented in this session spotlight ways in which a novel prognostic tool is demonstrating its value across a range of blood cancers.
  • The researchers used MRD to determine how long patients in the targeted-agents group should continue treatment.
  • These cells develop into specialized blood cells, such as red and white blood cells and platelets, that also carry the mutation.
  • By comparison, progression-free survival (PFS) for patients receiving the standard of care was 76.8% with a death rate of 7%.

AI Innovation for automated Detection and Classification of osteoporotic Fractures of the Spine in CT Scans - ImageBiopsy Lab launches IB Lab FLAMINGO

Retrieved on: 
Wednesday, November 29, 2023
Osteoporosis, RSNA, UCB, Gold, Abdomen, Spine, Bone fracture, Vertebral compression fracture, Patient, Orthopedic surgery, Radiation exposure, MSK, Medical Affairs Bureau, Fracture, Risk assessment, ZOO, Diagnosis, VFS, Partnership, Thorax, Pain, Hospital, AI, Physician, Quality of life, Dentistry, Medical imaging, Dietary supplement

IB Lab FLAMINGO analyzes any CT images of the upper extremities (thorax, abdomen) that include the spine.

Key Points: 
  • IB Lab FLAMINGO analyzes any CT images of the upper extremities (thorax, abdomen) that include the spine.
  • Developed by UCB , a global biopharmaceutical company, IB Lab FLAMINGO is integrated into ImageBiopsy Lab 's ZOO MSK platform, targeting hospitals to reduce overlooked spinal fractures and support early diagnosis and treatment of osteoporosis.
  • VIENNA, Nov. 29, 2023 /PRNewswire/ -- ImageBiopsy Lab, a pioneer in medical imaging, introduces IB Lab FLAMINGO at this year's RSNA conference.
  • Utilizing the gold standard Genant classification, IB Lab FLAMINGO highlights relevant fractures and empowers proactive treatment for healthcare professionals.